Chronic Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-02-21Clinical Trial Update: TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients [Phase 2]
A Phase II clinical trial of TGRX-678 in Chinese patients with chronic myeloid leukemia is currently recruiting.
-
FDA approval · 2025-02-19FDA Approved: NILOTINIB — Original Application (Cipla USA Inc.)
FDA approval of an Original Application for nilotinib by Cipla USA Inc., a generic version of Tasigna for treatment of Philadelphia chromoso…
-
CLINICAL_TRIALS trial_result · 2025-02-14Clinical Trial Update: Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response. [Phase 2]
Phase 2 study evaluating the efficacy and safety of asciminib in combination with imatinib in patients with chronic-phase chronic myeloid le…
-
CLINICAL_TRIALS trial_result · 2025-01-17Clinical Trial Update: Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib [Phase 2]
Phase 2 trial update on ponatinib in adults with imatinib-resistant chronic-phase chronic myeloid leukemia, describing its activity and safe…
-
FDA approval · 2025-01-08FDA Approved: IMATINIB MESYLATE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental ANDA for Imatinib Mesylate (Chartwell RX, LLC), enabling marketing of a generic version of the cancer drug.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-12-16Clinical Trial Update: Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib
A clinical trial update notes that a study evaluating vasoregulation function of the endothelium in patients with chronic myeloid leukemia t…
-
CLINICAL_TRIALS trial_result · 2024-12-13Clinical Trial Update: Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma [Phase 2]
Phase 2 trial evaluating dendritic cell therapy for acute myeloid leukemia, chronic myeloid leukemia, and multiple myeloma reports efficacy …
-
FDA approval · 2024-12-09FDA Approved: IMATINIB MESYLATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for imatinib mesylate from Mylan Pharmaceuticals, effectively authorizing a supplemental approva…
-
CLINICAL_TRIALS research · 2024-12-09Clinical Trial Update: Interaction Between Gut Microbiota and TKIs in Defining the Clinical Outcomes of Patients With CML
A ClinicalTrials.gov entry reports an ongoing study investigating how gut microbiota interacts with tyrosine kinase inhibitors to influence …
-
FDA label_change · 2024-12-03FDA Approved: BOSULIF — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for BOSULIF (bosutinib) from Pfizer, updating the drug’s labeling. This indicates a change to th…
-
FDA approval · 2024-12-03FDA Approved: BOSULIF — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for Bosulif (bosutinib) from Pfizer Laboratories Div Pfizer Inc, updating the drug's labeling.
-
FDA approval · 2024-12-03FDA Approved: PHYRAGO — Supplemental Application (Cycle Pharmaceuticals Ltd)
FDA approved a supplemental application for PHYRAGO (dasatinib) submitted by Cycle Pharmaceuticals Ltd.
-
CLINICAL_TRIALS research · 2024-11-26Clinical Trial Update: Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia [Phase 2]
This update discusses a Phase 2 trial evaluating the efficacy and safety of withdrawing tyrosine kinase inhibitors after a two-step dose red…
-
CLINICAL_TRIALS withdrawal · 2024-11-26Clinical Trial Update: IIT PH1 KDS-1001 in Patients With CML [Phase 1]
The IIT Phase 1 trial of KDS-1001 in chronic myeloid leukemia has been withdrawn.
-
FDA approval · 2024-11-22FDA Approved: IMKELDI — Original Application (Shorla Oncology Inc.,)
FDA approved IMKELDI (imatinib oral) under an original NDA from Shorla Oncology, authorizing a new imatinib product for several cancers incl…
-
CLINICAL_TRIALS trial_result · 2024-11-18Clinical Trial Update: Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Therapy
This completed clinical trial update analyzes real-world treatment patterns and outcomes for patients with chronic myeloid leukemia who are …
-
FDA approval · 2024-11-07FDA Approved: DANZITEN — Original Application (Azurity Pharmaceuticals, Inc.)
FDA approved the Original Application for DANZITEN (nilotinib) from Azurity Pharmaceuticals, establishing a branded nilotinib product for Ph…
-
CLINICAL_TRIALS trial_result · 2024-11-06Clinical Trial Update: MargheRITA (Remote Intelligence for Therapeutic Adherence) [NA]
A completed clinical trial named MargheRITA (Remote Intelligence for Therapeutic Adherence) sponsored by Advice Pharma Group srl studied tre…
-
CLINICAL_TRIALS research · 2024-11-04Clinical Trial Update: A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia [Phase 1]
A Phase 1 trial to evaluate the safety and tolerability of TQB3911 tablets in patients with BCR-ABL positive chronic myeloid leukemia, not y…
-
CLINICAL_TRIALS trial_result · 2024-10-30Clinical Trial Update: Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation [Phase 2]
Phase 2 clinical trial update on a Triplex CMV vaccine designed to prevent CMV infection in patients undergoing hematopoietic stem cell tran…
-
CLINICAL_TRIALS research · 2024-10-30Clinical Trial Update: Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML
This clinical trial update evaluates dose reduction of Radotinib as a first-line treatment for Philadelphia chromosome-positive chronic myel…
-
FDA approval · 2024-10-29FDA Approved: SCEMBLIX — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Scemblix (asciminib) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS research · 2024-10-28Clinical Trial Update: A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs [Phase 3]
This entry describes a Phase 3 clinical trial evaluating radotinib for chronic myeloid leukemia in chronic phase patients who failed or were…
-
CLINICAL_TRIALS trial_result · 2024-10-17Clinical Trial Update: CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML [Phase 2]
Phase 2 clinical trial evaluating CD34-selected allogeneic hematopoietic stem cell transplantation with myeloablative conditioning plus CD8+…
-
CLINICAL_TRIALS research · 2024-10-17Clinical Trial Update: Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial
This update discusses the long-term risk of a second primary malignancy in patients with chronic myeloid leukemia treated with imatinib in t…